Agenus | AGEN - Pre Tax Profit


Agenus reported $-10.61M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Agenus USD -10.61M 263.52M Dec/2025
Amgen USD 1.51B 2.41B Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Celldex Therapeutics USD -81.32M 14.27M Dec/2025
CSL USD 2.61B 1.21B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
Incyte USD 343.6M 46.34M Mar/2026
Intrexon USD -60.48M 27.09M Jun/2024
J&J USD 7.82B 2.86B Mar/2026
Jiangsu Hengrui CNY 2.56B 261.24M Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
MacroGenics USD -36.77M 21.84M Mar/2026
Merck EUR 401M 886.1M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Novartis USD 3.84B 802M Mar/2026
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Veracyte USD 29.97M 10.66M Mar/2026